Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Graham

Showing results (841-850 of 994) with videos related to

Pageof 100
Sort By:
Science (New York, N.Y.)|July 3, 2025
Consistent energy-diversity relationships in terrestrial vertebratesMarco Túlio P Coelho, Elisa Barreto, José Alexandre F Diniz-Filho, et al.
Journal of the American Association of Nurse Practitioners|September 14, 2018
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trialsSusan J Tofte, Kim Papp, Neil Sadick, et al.
Elife|October 15, 2014
Mitochondrial fusion but not fission regulates larval growth and synaptic development through steroid hormone productionHector Sandoval, Chi-Kuang Yao, Kuchuan Chen, et al.
The Lancet. Respiratory Medicine|June 28, 2021
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysisWilliam W Busse, Sally E Wenzel, Thomas B Casale, et al.
Insects|September 27, 2025
First Report of Two-Spot Cotton Leafhopper (<i>Amrasca biguttula</i> Ishida) (Hemiptera: Cicadellidae) on Commercial Cotton in the Southeastern United StatesIsaac L Esquivel, Tim Bryant, Sean Malone, et al.
The British Journal of Dermatology|December 2, 2017
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)M de Bruin-Weller, D Thaçi, C H Smith, et al.
Journal of the American College of Surgeons|December 27, 2016
Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid CancerMichael C Sullivan, Paul H Graham, Erik K Alexander, et al.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|February 8, 2019
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitisG Yosipovitch, M Reaney, V Mastey, et al.
The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.
Pageof 100

Showing results (841-850 of 994) with videos related to

Sort By:
Pageof 100
Science (New York, N.Y.)|July 3, 2025
Consistent energy-diversity relationships in terrestrial vertebratesMarco Túlio P Coelho, Elisa Barreto, José Alexandre F Diniz-Filho, et al.
Journal of the American Association of Nurse Practitioners|September 14, 2018
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trialsSusan J Tofte, Kim Papp, Neil Sadick, et al.
Elife|October 15, 2014
Mitochondrial fusion but not fission regulates larval growth and synaptic development through steroid hormone productionHector Sandoval, Chi-Kuang Yao, Kuchuan Chen, et al.
The Lancet. Respiratory Medicine|June 28, 2021
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysisWilliam W Busse, Sally E Wenzel, Thomas B Casale, et al.
Insects|September 27, 2025
First Report of Two-Spot Cotton Leafhopper (<i>Amrasca biguttula</i> Ishida) (Hemiptera: Cicadellidae) on Commercial Cotton in the Southeastern United StatesIsaac L Esquivel, Tim Bryant, Sean Malone, et al.
The British Journal of Dermatology|December 2, 2017
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)M de Bruin-Weller, D Thaçi, C H Smith, et al.
Journal of the American College of Surgeons|December 27, 2016
Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid CancerMichael C Sullivan, Paul H Graham, Erik K Alexander, et al.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|February 8, 2019
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitisG Yosipovitch, M Reaney, V Mastey, et al.
The British Journal of Dermatology|June 2, 2020
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitisA Wollenberg, L A Beck, A Blauvelt, et al.
Pageof 100